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Abstract
Background: The optimal time sequences for chemotherapy and radiation therapy after breast surgery for patients
with breast cancer remains unknown. Most of published studies were done for early breast cancer patients.
However, in Egypt advanced stages were the common presentation. This retrospective analysis aimed to assess the
optimum sequence for our population.
Methods: 267 eligible patients planned to receive adjuvant chemotherapy [FAC] and radiotherapy. Majority of
patients (87.6%) underwent modified radical mastectomy while, 12.4% had conservative surgery.
We divided the patients into 3 groups according to the sequence of chemotherapy and radiotherapy. Sixty-seven
patients (25.1%) received postoperative radiotherapy before chemotherapy [group A]. One hundred and fifty
patients (56.2%) were treated in a sandwich scheme (group B), which means that 3 chemotherapy cycles were
given prior to radiotherapy followed by 3 further chemotherapy cycles. A group of 50 patients (18.7%) was treated
sequentially (group C), which means that radiotherapy was supplied after finishing the last chemotherapy cycle.
Patients’ characteristics are balanced between different groups.
Results: Disease free survival was estimated at 2.5 years, and it was 83.5%, 82.3% and 80% for patient receiving
radiation before chemotherapy [group A], sandwich [group B] and after finishing chemotherapy [group C]
respectively (p > 0.5). Grade 2 pneumonitis, which necessitates treatment with steroid, was detected in 3.4% of our
patients, while grade 2 radiation dermatitis was 17.6%. There are no clinical significant differences between
different groups regarded pulmonary or skin toxicities.
Conclusion: Regarding disease free survival and treatment toxicities, in our study, we did not find any significant
difference between the different radiotherapy and chemotherapy sequences.
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Background
Adjuvant chemotherapy and radiotherapy are established
treatment of breast cancer. The optimal way to integrate
chemotherapy and radiation therapy after breast surgery
for patients with breast cancer remains unknown [1].
Generally, radiotherapy is used after completion of adju-
vant chemotherapy [2] but decisive data for a scientifi-
cally based decision on the optimal sequence are not
known.
Retrospective reviews have shown increased rates of
local-regional recurrence when radiation therapy is
delayed after surgery [3]. This has not been a uniform
finding, however, with other retrospective series report-
ing no increased risk of local recurrence when radiation
is delayed in order to administer chemotherapy [4-6].
There is also concern that delaying chemotherapy in
order to give radiation may increase the risk of distant
metastasis and ultimately affect survival [7,8]. In Egypt,
patients usually presented with advanced stage of cancer
and majority of patients underwent modified radical
mastectomy, which is different from patients’ character-
istic in other countries. We conducted this retrospective
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Methods
The present retrospective study was conducted on 267
breast cancer patients attending to South Egypt Cancer
institute, Assiut University over the period from January
2001 to June 2008. Eligible criteria for the retrospective
analysis were Patients ≥ 35 years of age, female gender,
performance status ≤ II according to ECOG scale, histo-
logical evidence of invasive breast cancer, non-meta-
static breast cancer planned to receive adjuvant
chemotherapy [FAC] and radiotherapy.
Surgery was done including either modified radical
mastectomy or breast conservative surgery.
Chemotherapy regime was six cycles of anthracycline-
based chemotherapy (FAC) were given to all patients.
FAC (5-fluorouracil 500 mg/m
2, adriamycin 50 mg/m
2,
and cyclophosphamide 500 mg/m
2) were given bolus
intravenous day one every 3 weeks.
Our Radiation target volume was chest wall, breast (in
case of breast conservative surgery) and supraclavicular
region if indicated. The supraclavicular region extended
from the level of cricothyroid groove to sternal angle.
The superior border of the chest wall and breast
matched with the lower border of the supraclavicular
field. The lower field border was at 1 cm below the
mammary fold, guided by the opposite breast, if mas-
tectomy had been performed. The medial border was
set at midline, with no specific attempt to cover the
internal mammary lymph nodes, while the lateral border
was set at mid-axillary line. In patient who underwent
modified radical mastectomy, we used 2D planning
h o w e v e r ,a n dw eu s e d3 Dp l a n n i n gf o rp a t i e n tu n d e r -
went breast conservative surgery. A complete 3D plan
was done, taken in consideration the ICRU 50 recom-
mendations (A certain degree of heterogeneity should
be kept within +7% and -5% of prescribed dose).
Daily fractions of 2Gy were given to both supraclavi-
cular (at 3 cm depth) and tangential chest fields (at
depth of isocenter), with a total dose of 50 Gy with
6MV photon using Linac (Siemens Mevatron). Patients
who had undergone conservative surgery received boost
dose to tumour site of 14Gy (2Gy daily fractions) with
electron beam of 9-12 MeV prescribed at the 90% iso-
dose depth, at the end of whole breast irradiation.
The patients were grouped according to the sequence
of chemotherapy and radiotherapy. Sixty - seven patients
(25.1%) were treated with radiotherapy postoperative
before chemotherapy [group A]. One hundred and fifty
patients (56.2%) were treated in a sandwich scheme
(group B) which means that 3 chemotherapy cycles
were given prior to radiotherapy followed by 3 further
chemotherapy cycles. A group of 50 patients (18.7%)
were treated sequentially (group C) which means that
radiotherapy was applied after finishing the last che-
motherapy cycle.
The observation period started at the time of surgery
with median follow up was 30 months. The distribution
of various categorical variables, in the total patients as
well as separately for the subgroups of A, B and C is
summarized in Table 1.
We reported grade 2 toxicity or higher; moderate pul-
monary toxicity means respiratory symptoms judged by
the clinician to be caused by radiotherapy and treated
with corticosteroids [9]. Grade 2 Skin toxicity defined as
moderate to brisk erythema or a patchy moist desqua-
mation, mostly confined to skin folds and creases; mod-
erate edema [10].
Statistical methods
Continuous variables were summarized by means. Cate-
gorical data were condensed by absolute and relative
values. Cross tabulations were created to compare fre-
quency distributions between subgroups. The Pearson ×
2-test was used to assess whether the associations dis-
played in those cross tabulations are statistically signifi-
cant. Disease free survival (DFS) curves were estimated
according to the Kaplan-Meier method. The log-rank
test was used for comparison of DFS-curves between
the subgroups according to sequencing of chemo- and
radiotherapy.
The global significance level for all statistical test pro-
c e d u r e sc o n d u c t e dw a sc h o s e na s=5 % .A l ls t a t i s t i c a l
analyses were conducted in an explorative manner.
Thus, with consideration of the explorative character of
the analysis, p-values of p = 0.05 can be interpreted as
statistically significant test results.
Results
All patients’ characteristics were summarized in Table 1;
from these data, we can report that median age among
our patients was 49.5 years. Premenopausal, perimenopau-
sal and postmenopausal women represented 40.7% (108
patients), 18% (48 patients) and 41.3% (111 patients)
respectively. Right sided breast cancer represent 56.6%
(116 patients), while 43.4% (151 patients) had left side.
Most of patients (181 patients) were stage II (67.8%),
stage I represent 6.7% (18 patients) while, sixty-eight
patients (25.5%) had stage III.
Majority of the patients (234 patients) which consti-
tuted 87.6% underwent modified radical mastectomy
(MRM) while, thirty-three patients (12.4%) had breast
conservative surgery (BCS).
The differences in patients’ characteristics among dif-
ferent groups of radiotherapy and chemotherapy
sequence are represented in Table 1. The Pearson x
2-
test was used to assess these differences and revealed no
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acteristic (p > 0.5) among different group.
Among our patients, we noticed that although the inci-
dence of respiratory symptoms was high there were mild
and self-limiting with most of cases showed resolution
within 12 months. Grade 2 pneumonitis, which necessi-
tates treatment with steroid, between our patients detected
in 3.4%, while grade 2 radiation dermatitis was 17.6%.
There are no clinical significant differences between differ-
ent groups regarded pulmonary or skin toxicities (Table
2). Cardiac toxicities were very low and not more than G1.
As shown in Table 3 disease free survival (DFS) was esti-
mated at 2.5 years, and it was 83.5%, 82.3% and 80% for
patient receiving radiation before chemotherapy [group
A], sandwich [group B] and after finishing chemotherapy
[group C] respectively, by applying Pearson x2-test, and
the differences was insignificant (p > 0.5). Figure 1 demon-
strate the Kaplan-Meier curves for disease free survival for
the three groups, using log-rank test, we did not find any
significant differences between different groups (p > 0.5).
Discussion
Chemotherapy and radiation therapy are typically not
given concurrently in patients with breast cancer
because of the widespread use of anthracycline-based
chemotherapy regimens and the concern for excessive
radiation toxicity with concurrent treatment. Hence,
it is necessary to decide how best to sequence sys-
temic and radiation therapies. This question arises for
both patients treated with lumpectomy and those
treated with mastectomy, however, the optimal
sequencing of adjuvant chemotherapy and radiother-
apy in breast cancer patients remains controversial
[11].
Many studies suggested that delaying the initiation of
radiotherapy might result in an increased likelihood of
local failure. Buchholz and his colleagues divided 105
patients with local-regional breast cancer into two
groups based on the timing of their radiation treat-
ments; early radiation group [patients began their radia-
tion within 6 months of their diagnosis] and delayed
radiation group [patients began their radiation after 6
months of their diagnosis]. They concluded that, delay
in the initiation of radiation for a period of 6 months or
greater from diagnosis resulted in a higher local failure
rate. Furthermore, this higher local failure rate was asso-
ciated with an increased rate of distant metastases and a
decreased overall survival rate [12].
Table 1 patients’ characteristics
Variable All patients [%] Group A [%] Group B [%] Group C [%] p
Total number 267 67 150 50
Age at diagnosis (Mean) year 49.5 50 49 50.3 0.9
Menopausal status
Premenopausal 108 [40.7] 26 [38.8] 62 [41.3] 20 [40] p > 0.5
perimenopausal 48 [18] 15 [22.4] 25 [16.7] 8 [16]
postmenopausal 111 [41.3] 26 [38.8] 63 [42] 22 [44]
Laterality p > 0.5
Right 116 [56.6] 32 [47.8] 60 [40] 24 [48]
Left 151 [43.4] 35 [55.2] 90 [60] 26 [52]
Stage p > 0.5
I 18 [6.7] 5 [7.5] 9 [6] 4 [8]
II 181 [67.8 39 [58.2] 109 [72.7] 33 [66]
III 68 [25.5] 23 [34.3] 32 [21.3] 13 [26]
Type of surgery p > 0.5
MRM 234 [87.6] 57 [85.1] 131 [87.3] 43 [86]
BCS 33 [12.4] 10 [14.9] 19 [12.7] 7 [14]
Hormonal receptor 151 [56.6] 41 [61.2] 79 [52.6] 31 [14] p > 0.5
Positive 116 [43.4] 26 [38.8] 71 [47.4] 19 [12]
Negative
Table 2 Treatment related toxicities
Variable All patients [%] Group A [%] Group B [%] Group C [%] p
pulmonary complication GII 9 [3.4] 3 [4.5] 4 [2.7] 2 [4] > 0.05
Skin toxicity GII 47 [17.6] 16 [24] 21 [14] 10 [20] > 0.05
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delaying irradiation to the intact breast on 474 patients
underwent lumpectomy and intact breast irradiation for
early stage invasive breast cancer. Chemotherapy was
administered to 84 patients with median follow-up was
62 months. They concluded that delays in the initiation
of irradiation are associated with increased risk of
relapse in the breast. When possible, the interval
between definitive breast surgery (lumpectomy or re-
excision) and the initiation of radiation therapy should
be fewer than 120 days [13]. Recht and his colleagues
randomized 244 patients with clinical stage I or II breast
carcinoma after surgery to receive chemotherapy either
before or after radiotherapy. they suggested that, it is
preferable to give 12 weeks of chemotherapy before irra-
diation, rather than radiotherapy first, to patients at sub-
stantial risk for systemic recurrence of cancer. Although
their results suggest that the effect of the delay in initi-
ating chemotherapy may be greatest for patients with
the highest risk of subclinical systemic disease (i.e.,
those with four or more positive nodes) and that the
delay in initiating radiotherapy may be most detrimental
to patients with close or positive margins of the resected
tumour. In addition, extrapolating the results of this trial
to other regimens, particularly those with more pro-
longed intervals between surgery and radiotherapy (e.g.,
six months or more), may be misleading [14]. Update of
this trail with 135 months median follow-up for surviv-
ing patients, there were no significant differences
between the Chemotherapy-first and RT-first arms in
time to any event, distant metastasis, or death. Sites of
first failure were also not significantly different. How-
ever, this study has several limitations. The statistical
Table 3 2.5 years DFS among each group
Group A Group B Group C P-value
83.5 81.3 80 0.90
Figure 1 Disease free survival of different groups.
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analyses must be viewed with special caution [15]. In
addition, many studies suggest that delaying the initia-
tion of radiotherapy may result in an increased likeli-
hood of local failure [16].
Buchholz and his colleagues conducted a retrospective
analysis of 124 patients with lymph node-negative breast
cancer, underwent breast-conserving surgery with axil-
lary dissection, followed by chemotherapy and radiation
therapy. The outcome of 68 patients who received che-
motherapy first was compared with that of 56 patients
who received radiation first. There were no statistically
significant differences in local control, disease-free survi-
val, or overall survival between the two groups. They
concluded that chemotherapy can be giving before
radiation in lymph node-negative breast cancer without
compromising local control. Given the concerns about
increased distant metastases if radiation is given first,
the chemotherapy-radiation sequence is recommended
[17].
Contrary to above results, Leonard and his colleagues
failed to identify any surgery-radiotherapy interval that
resulted in increased local recurrence if radiotherapy
was delayed for administration of adjuvant chemother-
apy in breast cancer patients. They studied the records
of 262 women with 264 cases of breast cancer. Group I
contained 105 patients treated with conservative surgery,
chemotherapy, and radiotherapy. Group II contained
157 patients (used as a concurrent control) treated with
conservative surgery and radiotherapy only. There were
no significant differences in local recurrence in any sur-
gery-radiotherapy interval within each group. However,
this failure may be due to the heterogeneous population
of breast cancer patients, and because group II did not
receive chemotherapy [6].
A retrospective analysis aimed to assess the role of
sequencing in patients after mastectomy was conducted.
They studied records of a total of 212 patients. Eligible
patients had a stage III breast cancer and received adju-
vant chemotherapy and radiotherapy after mastectomy
and axillary dissection. Eighty-six patients were treated
sequentially (chemotherapy followed by radiotherapy)
(SEQ-group), 70 patients had a sandwich treatment
(SW-group) and 56 patients had simultaneous chemo-
radiation (SIM-group). 5-year overall- and disease free
survival were 53.2%/56%, 38.1%/32% and 64.2%/50%, for
the sequential, sandwich and simultaneous regime,
respectively, which differed significantly in the univariate
analysis (p = 0.04 and p = 0.03). The 5-year locoregional
or distant recurrence free survival showed no significant
differences according to the sequence of chemo- and
radiotherapy. They concluded that, no clear advantage
can be stated for any radio- and chemotherapy sequence
in breast cancer therapy so far [1].
National comprehensive cancer network panel [2]
recommended that radiotherapy should be started after
finishing chemotherapy however; this is based on single
prospective trail [14] and its update [15] with limitations
as mentioned above.
French multicenter phase III randomized trial (ARCO-
SEIN trial) enrolled 716 patients. Sequential treatment
of Chemotherapy administered first followed by RT was
compared with concurrent treatment of Chemotherapy
administered with RT. The Chemotherapy regimen con-
sisted of mitoxantrone (12 mg/m2), fluorouracil (500
mg/m2), and cyclophosphamide (500 mg/m2) on day 1,
which was repeated every 21 days for six courses. RT
was delivered to the breast and, when indicated, to the
regional lymphatics. There was no statistically significant
difference on 5-year DFS, locoregional recurrence-free
survival, metastasis-free survival, or overall survival.
Nevertheless, in the node-positive subgroup, the 5-year
LRFS was statistically better in the concurrent arm (97%
in concurrent v 91% in sequential; P = .02), correspond-
ing to a risk of locoregional recurrence decreased by
39% (hazard ratio, 0.61; 95% CI, 0.38 to 0.93). They con-
cluded that, this treatment protocol remains an appeal-
ing clinical option for patients at a high risk of
recurrence [18]. Ismaili et al evaluated the efficacy and
safety of the concomitant use of anthracycline with
radiotherapy after mastectomy or BCS. The adjuvant
treatment, based on anthracycline and concurrent RT,
reduced breast cancer relapse rate, and significantly
improved LRFS, EFS and OS in patients receiving more
than 1 cycle of concurrent Chemotherapy. There were
more hematologic and non hematologic toxicities in the
anthracycline group compared to those received CMF
[19].
Zellars RC etal conducted a single-arm feasibility trial
testing anthracycline-based chemotherapy and concur-
rent partial breast irradiation (PBI). They concluded that
PBI with concurrent dose-dense doxorubicin and cyclo-
phosphamide (ddAC) is feasible with acceptable local
and systemic toxicity [20].
The different treatment sequences at our department
were related to changing our department policies as a
part of radiation therapy evolution. Our treatment pro-
tocols arranged for immediate postoperative radiation
before chemotherapy. However after June 2002, we
established sandwich scheme which means that 3 che-
motherapy cycles were given prior to radiotherapy fol-
lowed by 3 further chemotherapy cycles. Sandwich
scheme was based on the data reported by Recht and
his colleagues as they noted that delaying breast irradia-
tion longer than 16 weeks after tumour excision resulted
in a higher incidence of breast relapses. While Adminis-
tration of irradiation first led to a higher incidence of
distant metastases [21]. With further evolution of
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ish chemotherapy first before radiation, similar to other
cancer centres protocols based on many studies [14,15].
We used three dimensions planning only for BCS,
however two dimensions planning is used in-patient
underwent mastectomy. This is based in study done at
South Egypt Cancer Institute during the period of time
from February 2001 to October 2003. Its results is pub-
lished in 2004 and demonstrated that there is significant
dosimetric improvement from two dimensions planning
to three dimensions planning in both patient underwent
mastectomy and patient underwent BCS. However, this
improvement is marked in BCS that is reflected by
decrease skin toxicity [22].
Moderate radiation pneumonitis, which necessitates
treatment with steroid, between our patients was
detected in 3.4% of patients. This result matches with
Lingos [23] and Elsayed [22], as they reported incidences
of radiation pneumonitis that required steroid 2.9% and
2.7% respectively. Lind and his colleagues [24] reported
that 9% of patients had radiation pneumonitis that
required steroid. This difference explained by three rea-
sons, the first is that 95% of patients received internal
mammary irradiation, the second is that 21% of patients
received CMF regimen which contains methotrexate
with high tendency to cause pulmonary complications.
and the third reason, is higher percentage of irradiated
lung volume (32%) in that study that received ≥ 25 Gy.
In addition, Hanna and his colleagues [25] reported
more incidences, 15% of patients, required steroid for
treatment of radiation pneumonitis, and this may be
explained by the use of paclitaxol which known to
reduce the lung tolerance.
Acute radiation dermatitis (G 2) was detected in 17.6%
and this finding is in agreement with other studies [22].
The present study showed a 2.5-year relapse free survival
rate was 83.5%, 82.3% and 80% for patient receiving radia-
tion before chemotherapy [group A], sandwich [group B]
and after finishing chemotherapy [group C] respectively (p
> 0.5). This was similar to that (81%) reported by Ragaz
[26] and to that (83.5%) reported by Elsayed [22].
Our study did not find any significant difference in
survival or toxicities between the different radiotherapy
sequences which is inconsistent with the above men-
tioned studies however we have many limitation. This is
a retrospective study done in different time period as
arm (A) was done before June 2002, arm (B) between
June 2002 and June 2005, while arm (C) after that; how-
ever our patients’ characteristics are matched. Follow up
period of our patients is short because this study is lim-
ited by follow up of last sequence (arm C). The number
of cases in arm C is small as many patients received tax-
ane based adjuvant chemotherapy that might be ineligi-
ble for our analysis.
Regarding disease free survival or treatment toxicities,
our study did not find any significant difference between
the different radiotherapy sequences, which is inconsis-
tent with the above-mentioned studies.
We concluded that until now we have no optimal
sequence, and it is better to conduct a randomized trial
to answer this question.
Author details
1Department of Radiation Oncology, South Egypt Cancer Institute, Assiut
University, Egypt.
2Department of Medical Oncology, South Egypt Cancer
Institute, Assiut University, Egypt.
3Department of surgical Oncology, South
Egypt Cancer Institute, Assiut University, Egypt.
Authors’ contributions
all authors have same contributions in collecting data from patients’ files.
First, second, third and fourth authors underwent statistical analysis. The first
author underwent the remaining works (abstract, background, methods,
results, discussion, and references). The second author underwent
submission of the manuscript. The sixth author did English revision. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 April 2011 Accepted: 16 October 2011
Published: 16 October 2011
References
1. Piroth MD, Pinkawa Michael, Gagel Bernd, Stanzel Sven, Asadpour Branka,
Eble MJ: Sequencing chemotherapy and radiotherapy in locoregional
advanced breast cancer patients after mastectomy - a retrospective
analysis. BMC Cancer 2008, 8:114.
2. National Comprehensive Cancer Network (NCCN) version 2. 2011.
3. Huong J, Barbera L, Brouwers M, et al: Does delay in starting treatment
affect the outcome of radiotherapy? A systematic review. J Clin Oncol
2003, 21:555-563.
4. Vujovic O, Perera F, Dar AR, et al: Does delay in breast irradiation
following conservative breast surgery in node-negative breast cancer
patients have an impact on risk of recurrence? Int J Radiat Oncol Biol Phys
1998, 40:869-874.
5. Meek AG, Park TL, Weiss TA, et al: Effect of delayed radiation therapy on
local control in breast conservation therapy. Radiology 1996, 200:615-619.
6. Leonard CE, Wood ME, Zhen B, et al: Does administration of
chemotherapy before radiotherapy in breast cancer patients treated
with conservative surgery negatively impact local control? J Clin Oncol
1995, 13:2906-2915.
7. Buzdar AU, Kau SW, Smith TL, et al: The order of administration of
chemotherapy and radiation and its effect on the local control of
operable breast cancer. Cancer 1993, 71:3680-3684.
8. Brufman G, Sulkes A, Biran S: Adjuvant chemotherapy with and without
radiotherapy in stage II breast cancer. Biomed Pharmacother 1988,
42:351-355.
9. Wennberg B, Giovana G, Sundbom L, Savne G, Lind P: Early response o
lung in breast cancer irradiation: Radiologic density changes measured
by CT and symptomatic radiation pneumonitis. Int J Radiat Oncol Biol
Phys 2002, 52:1196-1206.
10. World Health Organization: COMMON TOXICITY CRITERIA (CTC Version
2.0). 1999 [http://ctep.cancer.gov/protocoldevelopment/
electronic_applications/docs/ctcv20_4-30-992.pdf], Accessed on 11 April
2011.
11. Bellon JR, Harris JR: Chemotherapy and radiation therapy for breast
cancer: what is the optimal sequence? J Clin Oncol 2005, 23(1):30-40.
12. Buchholz TA, Hunt KK, Amosson CM, Tucker SL, Strom EA, McNeese MD,
Buzdar AU, Singletary SE, Hortobagyi GN: Sequencing of chemotherapy
and radiation in lymph node-negative breast cancer. Cancer J Sci Am
1999, 5:159-164.
Abbas et al. International Archives of Medicine 2011, 4:35
http://www.intarchmed.com/content/4/1/35
Page 6 of 713. Hartsell WF, Recine DC, Griem KL, Murthy AK, Hartsell WF, Recine DC,
Griem KL, Murthy AK: Delaying the initiation of intact breast irradiation
for patients with lymph node positive breast cancer increases the risk of
local recurrence. Cancer 1995, 76:2497-2503.
14. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF,
Shulman LN, Harris JR: The sequencing of chemotherapy and radiation
therapy after conservative surgery for early-stage breast cancer. N Engl J
Med 1996, 334:1356-1361.
15. Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ,
Harris JR, Recht A: Sequencing of chemotherapy and radiation therapy in
early-stage breast cancer: updated results of a prospective randomized
trial. Journal of Clinical Oncology 2005, 23:1934-1940.
16. Recht A, Come SE, Gelman RS, Goldstein M, Tishler S, Gore SM, Abner AL,
Vicini FA, Silver B, Connolly JL: Integration of conservative surgery,
radiotherapy, and chemotherapy for the treatment of early-stage, node-
positive breast cancer: sequencing, timing, and outcome. J Clin Oncol
1991, 9:1662-1667.
17. Buchholz TA, Austin-Seymour MM, Moe RE, Ellis GK, Livingston RB,
Pelton JG, Griffin TW: Effect of delay in radiation in the combined
modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1994,
28(3):783-4.
18. Toledano AH, Bollet MA, Fourquet A, Azria D, Gligorov J, Garaud P, Serin D,
Bosset JF, Miny-Buffet J, Favre A, LeFoch O, Calais G: Does concurrent
radiochemotherapy affect cosmetic results in the adjuvant setting after
breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase
III study: patients’ and doctors’ views. Int J Radiat Oncol Biol Phys 2007,
68(1):66-7.
19. Ismaili N, Elmajjaoui S, Lalya I, Boulaamane L, Belbaraka R, Abahssain H,
Aassab R, Benjaafar N, El Guddari Bel K, El Mesbahi O, Sbitti Y, Ismaili M,
Errihani H: Anthracycline and concurrent radiotherapy as adjuvant
treatment of operable breast cancer: a retrospective cohort study in a
single institution. BMC Res Notes 2010, 3:247.
20. Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S,
Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E,
Davidson NE, Wolff AC: Feasibility trial of partial breast irradiation with
concurrent dose-dense doxorubicin and cyclophosphamide in early-
stage breast cancer. J Clin Oncol 2009, 27:2816-22.
21. Recht A, Come SE, Henderson IC, et al: Sequencing of chemotherapy and
radiotherapy after conservative surgery for early-stage breast cancer. N
Engl J Med 1996, 334:1356-1361.
22. Elsayed M: Dosimetric improvement and its clinical impact following
planning of breast irradiation. MD thesis, South Egypt Cancer Institute
library, Assiut University; 2004.
23. Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR: Radiation
pneumonitis in breast cancer patients treated with conservative surgery
and radiation therapy. Int J Radiat Oncol Biol Phys 1991, 21:355-60.
24. Lind PARM, Rosfors S, Wennberg B, et al: Pulmonary function following
adjuvant chemotherapy and radiotherapy for breast cancer and the
issue of three-dimensional treatment planning. Radiother Oncol 1998,
49:245-54.
25. Hanna YM, Baglan KL, Stromberg JS, et al: Acute and subacute toxicity
associated with concurrent adjuvant radiation therapy and paclitaxel in
primary breast cancer therapy. Breast J 2002, 8:149-53.
26. Ragaz J, Ivo AOlivotto, John JSpinelli, et al: Locoregional Radiation Therapy
in Patients With High-Risk Breast Cancer Receiving Adjuvant
Chemotherapy: 20-Year Results of the British Columbia Randomized
trial. Journal of the National Caner Institute 2005, 97(2):116-26.
doi:10.1186/1755-7682-4-35
Cite this article as: Abbas et al.: The optimal sequence of radiotherapy
and chemotherapy in adjuvant treatment of breast cancer. International
Archives of Medicine 2011 4:35.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Abbas et al. International Archives of Medicine 2011, 4:35
http://www.intarchmed.com/content/4/1/35
Page 7 of 7